Clinical Trials Browser

Recruiting × Uterine Cervical Neoplasms × anlotinib × Clear all

NCT05817214 2024-04-19

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms